Cytokinetics Inc (KK3A)

Currency in EUR
32.80
-0.40(-1.20%)
Delayed Data·
KK3A is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.8032.80
52 wk Range
26.4055.50
Key Statistics
Bid/Ask
33.60 / 33.80
Prev. Close
33.2
Open
32.8
Day's Range
32.8-32.8
52 wk Range
26.4-55.5
Volume
1
Average Volume (3m)
318
1-Year Change
-34.65%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KK3A Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Cytokinetics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Cytokinetics Inc Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Compare KK3A to Peers and Sector

Metrics to compare
KK3A
Peers
Sector
Relationship
P/E Ratio
0.0x−1.2x−0.6x
PEG Ratio
0.00−0.050.00
Price/Book
0.0x1.8x2.6x
Price / LTM Sales
0.0x7.5x3.3x
Upside (Analyst Target)
0.0%294.5%40.2%
Fair Value Upside
Unlock23.7%5.1%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KK3A Income Statement

People Also Watch

21.19
SRPT
-2.87%
55.19
BMNR
-4.53%
29.78
RARE
+0.30%
49.67
PTCT
+1.74%
128.01
INSM
+0.17%

FAQ

What Stock Exchange Does Cytokinetics Inc Trade On?

Cytokinetics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Cytokinetics Inc?

The stock symbol for Cytokinetics Inc is "KK3A."

What Is the Cytokinetics Inc Market Cap?

As of today, Cytokinetics Inc market cap is 4.03B.

What Is Cytokinetics Inc's Earnings Per Share (TTM)?

The Cytokinetics Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is KK3A a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cytokinetics Inc Stock Split?

Cytokinetics Inc has split 0 times.

What is the current trading status of Cytokinetics Inc (KK3A)?

As of 18 Aug 2025, Cytokinetics Inc (KK3A) is trading at a price of 32.80, with a previous close of 33.20. The stock has fluctuated within a day range of 32.80 to 32.80, while its 52-week range spans from 26.40 to 55.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.